A Diagnostic Assay for Multiple Sclerosis Based on EBV

Researchers have developed a second-generation diagnostic test to identify a specific autoantibody signature that can predict multiple sclerosis (MS) years before clinical symptoms appear. By isolating a monoclonal antibody from an MS patient’s B cells, the study identified a conserved protein motif that triggers an immune response. This signature appears to result from molecular mimicry between the Epstein-Barr virus protein BRRF2 and host CNS proteins like vimentin. The refined Luminex assay uses consensus peptides to achieve high precision and can detect these markers in approximately 11% of MS cases. This tool offers a promising method for early risk assessment and the potential for preventative medical interventions.